BR9508019B1 - Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica. - Google Patents

Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica.

Info

Publication number
BR9508019B1
BR9508019B1 BRPI9508019-8A BR9508019A BR9508019B1 BR 9508019 B1 BR9508019 B1 BR 9508019B1 BR 9508019 A BR9508019 A BR 9508019A BR 9508019 B1 BR9508019 B1 BR 9508019B1
Authority
BR
Brazil
Prior art keywords
nucleic acid
pharmaceutical composition
host cell
expression vector
pantropic
Prior art date
Application number
BRPI9508019-8A
Other languages
English (en)
Other versions
BR9508019A (pt
Inventor
Roman Urfer
Leonard G Presta
John W Winslow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962278&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9508019(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9508019A publication Critical patent/BR9508019A/pt
Publication of BR9508019B1 publication Critical patent/BR9508019B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI9508019-8A 1994-06-03 1995-06-01 Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica. BR9508019B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25393794A 1994-06-03 1994-06-03
PCT/US1995/006918 WO1995033829A1 (en) 1994-06-03 1995-06-01 Pantropic neurotrophic factors

Publications (2)

Publication Number Publication Date
BR9508019A BR9508019A (pt) 1997-09-09
BR9508019B1 true BR9508019B1 (pt) 2012-06-12

Family

ID=22962278

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9508019-8A BR9508019B1 (pt) 1994-06-03 1995-06-01 Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica.

Country Status (17)

Country Link
US (6) US5728803A (pt)
EP (1) EP0763107B1 (pt)
JP (1) JPH10501138A (pt)
CN (1) CN1159439C (pt)
AT (1) ATE280825T1 (pt)
AU (1) AU695144B2 (pt)
BR (1) BR9508019B1 (pt)
CA (1) CA2191064C (pt)
DE (1) DE69533698T2 (pt)
ES (1) ES2231786T3 (pt)
FI (1) FI120237B (pt)
IL (1) IL113983A0 (pt)
MX (1) MX9605971A (pt)
NO (1) NO317938B1 (pt)
NZ (1) NZ287762A (pt)
PT (1) PT763107E (pt)
WO (1) WO1995033829A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
DE19637718A1 (de) * 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
NZ335207A (en) * 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
EP0977860A1 (en) * 1997-04-25 2000-02-09 Genentech, Inc. Ngf variants
US6365373B2 (en) 1997-04-25 2002-04-02 Genentech, Inc. Nucleic acids encoding NGF variants
US7452863B1 (en) 1997-04-29 2008-11-18 Genentech, Inc. NGF variants
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) * 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
GB0024550D0 (pt) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
DK1401498T3 (da) * 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
DK1891966T3 (da) 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
EP1841858A4 (en) * 2004-12-30 2010-02-10 Univ Johns Hopkins PROCESS FOR HIGHLY EFFICIENT SURVIVAL OR BZW. For the highly efficient proliferation of human embryonic stem cells in culture
ES2777652T3 (es) * 2006-12-21 2020-08-05 H Lundbeck As Modulación de la actividad de proneurotrofinas
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
US8447409B2 (en) * 2008-10-15 2013-05-21 Cochlear Limited Electroneural interface for a medical implant
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
ES2966133T3 (es) * 2016-03-18 2024-04-18 Staidson Beijing Biopharmaceuticals Co Ltd Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
CN112409471B (zh) * 2016-04-13 2022-07-29 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
CN110183536B (zh) * 2018-02-22 2021-01-15 中国科学院遗传与发育生物学研究所 一种复合支架材料及其应用
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ，インク． 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
CN110812532A (zh) * 2019-08-20 2020-02-21 中山大学 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169764A (en) * 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US5349055A (en) * 1992-03-06 1994-09-20 Persson Hakan B Nerve growth factor having altered receptor binding specificities
US5488099A (en) * 1992-03-06 1996-01-30 Persson, Deceased; Hakan B. Multifunctional chimeric neurotrophic factors
WO1993025684A1 (en) * 1992-06-12 1993-12-23 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
AU1282895A (en) * 1993-12-29 1995-07-17 Sumitomo Pharmaceuticals Company, Limited Novel human ciliary neurotrophic factor
US7144983B1 (en) * 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5728803A (en) * 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors

Also Published As

Publication number Publication date
CA2191064C (en) 2009-11-03
JPH10501138A (ja) 1998-02-03
WO1995033829A1 (en) 1995-12-14
FI964833A0 (fi) 1996-12-03
DE69533698D1 (de) 2004-12-02
NO965123L (no) 1997-02-03
NO317938B1 (no) 2005-01-10
EP0763107A1 (en) 1997-03-19
US5981480A (en) 1999-11-09
NZ287762A (en) 1999-01-28
ATE280825T1 (de) 2004-11-15
AU695144B2 (en) 1998-08-06
CA2191064A1 (en) 1995-12-14
US20100184656A1 (en) 2010-07-22
US5728803A (en) 1998-03-17
IL113983A0 (en) 1995-10-31
EP0763107B1 (en) 2004-10-27
US20060270838A1 (en) 2006-11-30
CN1159439C (zh) 2004-07-28
CN1153528A (zh) 1997-07-02
FI964833A (fi) 1996-12-03
ES2231786T3 (es) 2005-05-16
AU2659295A (en) 1996-01-04
US7935671B2 (en) 2011-05-03
US6333310B1 (en) 2001-12-25
US7528233B2 (en) 2009-05-05
BR9508019A (pt) 1997-09-09
PT763107E (pt) 2005-02-28
FI120237B (fi) 2009-08-14
US6503728B1 (en) 2003-01-07
MX9605971A (es) 1997-12-31
DE69533698T2 (de) 2006-02-09
NO965123D0 (no) 1996-12-02

Similar Documents

Publication Publication Date Title
BR9508019B1 (pt) Ácido nuclÉico, vetor de expressço, cÉlula hospedeira e composiÇço farmacÊutica.
WO2001079443A3 (en) Albumin fusion proteins
DK0556345T3 (da) Retrovirale vektorer,som er egnede til genterapi
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
DE69331484D1 (de) N-Acetylglucosaminyl-Transferase, dafür kodierendes Gen, entsprechende Vektoren und transformierte Wirte und Herstellungsverfahren dafür
WO1997003192A3 (en) Chromosome 1 gene and gene products related to alzheimer's disease
CY1107552T1 (el) Ly6h γονιδιο
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
GB2367061A (en) Peptides
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
WO2002004677A8 (en) Methods for diagnosis and treatment of psychiatric disorders
WO1999049038A3 (en) Human calcium-binding proteins
BR9609631A (pt) Isocromanos 1,6-dissubstituídos para tratamento de cefaléias de enxaqueca
WO2001042474A3 (en) Interferon-like molecules and uses thereof
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
ATE293695T1 (de) Humanes akt-3 protein
NO981707L (no) Xylanase, oligonukleotidsekvens som koder for xylanase og anvendelse derav
NZ334762A (en) Human DNase I variants having binding affinity to actin
WO2001014415A3 (en) Egfh2 genes and gene products
WO1999043832A3 (en) Human proteinase molecules
CA2188264A1 (en) Isolated nucleic acid molecule coding for fibroblast activation protein .alpha. and uses thereof
AU2001267433A1 (en) Nucleic acid molecules encoding a protein interacting with ser/thr kinase akt
WO1998050425A3 (en) Human tsc-22-like proteins
TH13148S1 (th) ขวดรูปหุ่นยนต์

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061552/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132261-03.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: ELI LILLY AND COMPANY (NZ) LIMITED, ELI LILLY AND COMPANY, F. HOFFMANN-LA ROCHE AG., GENENTECH, INC. E HOECHST AKTIENGESELLSCHAFT

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130004810, DE 17/10/2013